SK bioscience completed on Thursday a periodic World Health Organization Good Manufacturing Practice (WHO GMP) review through a documentary assessment alone, without an on-site inspection, at its Andong L HOUSE manufacturing facility, the company said. According to the company, the three-year GMP review covered four WHO prequalification-approved vaccines: influenza vaccines SKYCellflu and SKYCellflu Quadrivalent, varicella vaccine SKYVaricella and typhoid vaccine SKYTyphoid. WHO GMP inspections typically require visits to production sites to verify manufacturing and quality management systems in person. For the Andong facility, the review was completed solely through submitted documentation, which SK bioscience said reflects WHO's confidence in the site's operations and quality systems. The company said the outcome is also linked to the growing international credibility of Korea's pharmaceutical regulatory system following the designation of the Ministry of Food and Drug Safety as a WHO-Listed Authority. Under WHO's Regulatory Reliance policy, the organization can draw on the inspection r